
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. is positioned favorably due to its innovative PREDATOR platform, which allows for the development of novel therapeutics aimed at enhancing the body's immune response to cancer. The company has shown potential for significant growth, as evidenced by its focus on conditionally activated INDUKINE molecules that selectively target the tumor microenvironment, thus addressing the limitations of traditional therapies. Financial metrics indicate a positive trajectory, as reflected in the enhanced guidance for Core Funds From Operations (Core FFO), which demonstrates strong demand and operational performance alongside modest expense growth.
Bears say
The analysis indicates a negative outlook for Werewolf Therapeutics, primarily due to the downward revision in full-year same-store revenue growth forecasts, reflecting weakened operational performance. The company reported a decline in year-over-year revenues of 30 basis points alongside a 3.8% increase in expenses, resulting in a notable decrease of 2.6% in net operating income. Furthermore, the average effective rental rate also experienced a 50 basis point decline, signaling challenges in maintaining revenue growth amidst competitive leasing conditions.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares